BioMark Diagnostics Engages LHA for Investors Relations

Press Releases |

Vancouver, British Columbia - BioMark Diagnostics Inc. (BUX:CNX) (FSE: 20B) (BMKDF) announces that it has engaged LHA to support its investor relations program in the U.S. market.

“We recognize the importance of expanding our investor relations outreach,” said BioMark President and CEO Rashid Ahmed.  “In recent years, the U.S. investment community has shown significant interest in the biotechnology sector and we are excited to introduce BioMark and our novel, disruptive technology to this receptive market.  Given their understanding of the opportunity, and proven track record for establishing messaging that resonates with investors and increasing Street awareness for companies like BioMark, we view LHA as an ideal choice.  LHA is the right partner for BioMark at the right time.”                                                                                    

About LHA

Founded in 1984, LHA (formerly Lippert Heilshorn & Associates) is a leading provider of investor relations services. Staffed by a team of professionals with deep experience across multiple industry sectors, LHA partners with public and private companies to define objectives, set strategy and implement custom-designed programming utilizing industry best practices. By creating client identity and communicating strategic vision, LHA builds awareness, enthusiasm and sponsorship among target audiences to maximize shareholder value.

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions that can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors. For more information, please visit www.biomarkdiagnostics.com.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website www.thecse.ca.

Company Contact

Rashid Ahmed Bux

President & CEO

BioMark Diagnostics Inc.

604-282-6567

info@biomarkdiagnostics.com

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Veritas Pharma Inc.

Veritas Pharma Inc, formerly Seashore Organic Medicine Inc is an emerging producer and distributor of medical marijuana.

Private Markets

Lyft

Lyft matches drivers using their own personal vehicles with passengers who request rides through the smartphone app, and the passengers pay automatically through the app. When using Lyft, passengers have…

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…